Pyxis Oncology, Inc. (PYXS) - Dilution Analysis

10-Q filing | 63.5M shares outstanding

S-3 filing: Pyxis Oncology, Inc. is offering shares of common stock, shares of preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities.

10-Q filing | 62.6M shares outstanding

10-Q filing | 61.9M shares outstanding

10-Q filing | 61.0M shares outstanding

10-K filing | 58.4M shares outstanding

10-Q filing | 60.7M shares outstanding

10-Q filing | 60.5M shares outstanding

10-Q filing | 58.9M shares outstanding

S-3 filing: This S-3 filing registers for resale up to 10,460,586 shares of common stock by selling stockholders, consisting of shares held by them and shares issuable upon exercise of pre-funded warrants.

10-K filing | 58.1M shares outstanding

8-K filing: Pyxis Oncology, Inc. entered into a securities purchase agreement for a private placement with institutional and accredited investors to issue and sell shares of common stock and pre-funded warrants, anticipating gross proceeds of approximately $50 million.

10-Q filing | 41.3M shares outstanding

POS AM filing: This prospectus relates to an aggregate of up to 1,003,921 shares of common stock issuable upon the future exercise of certain outstanding warrants to purchase shares of our Common Stock in connection with the acquisition of Apexigen by Pyxis Oncology, which was completed on August 23, 2023, plus an indeterminate number of shares of our Common Stock that may be issued as a result of stock splits, stock dividends, recapitalizations or similar events as described in the warrant agreements governing the Apexigen Warrants.

10-Q filing | 38.4M shares outstanding

10-Q filing | 35.4M shares outstanding

10-K filing | 37.0M shares outstanding

10-Q filing | 32.6M shares outstanding

S-3 filing: Pyxis Oncology files an S-3 to offer shares of common stock, preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities. The aggregate offering price is up to $250,000,000.

10-Q filing | 32.5M shares outstanding

10-Q filing | 32.8M shares outstanding

10-K filing | 32.8M shares outstanding

10-Q filing | 32.8M shares outstanding

S-1/A filing: This S-1/A filing is an amendment to a registration statement for a proposed offering of common stock. It includes details about the offering size, potential proceeds, use of proceeds, and shares outstanding, as well as information regarding potential future employment agreements. It outlines an offering of 9,500,000 shares of common stock, with an underwriter option for an additional 1,425,000 shares, and estimates net proceeds of approximately $128.6 million based on an assumed IPO price of $15.00 per share.

S-1/A filing: This S-1/A filing describes a common stock offering of 8,340,000 shares with an underwriters' option to purchase up to 1,251,000 additional shares. It also details information regarding shares outstanding, use of proceeds, and agreements with named executive officers.

S-1 filing: This S-1 filing describes a proposed offering of common stock, including an underwriter's option to purchase additional shares. It details the company's intent to use the proceeds for advancing its programs and general corporate purposes, and mentions new employment agreements and equity incentive plans.